Medtronic Says FDA OKs Expanded Indication For Cardiac Resynchronization Therapy NASDAQ The expanded indication includes New York Heart Association Class II heart failure patients with a left ventricular ejection fraction of less than or equal to 30 percent, left bundle branch block, and a QRS duration greater than or equal to 130 ... Medtronic Receives FDA Approval to Treat Mildly Symptomatic Heart Failure ... |
